Compare LNTH & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LNTH | BLCO |
|---|---|---|
| Founded | 1956 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Ophthalmic Goods |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 5.9B |
| IPO Year | 2014 | 2022 |
| Metric | LNTH | BLCO |
|---|---|---|
| Price | $82.79 | $15.71 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 12 |
| Target Price | ★ $87.00 | $18.45 |
| AVG Volume (30 Days) | ★ 612.4K | 348.1K |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.41 | N/A |
| Revenue | $343,374,000.00 | ★ $5,101,000,000.00 |
| Revenue This Year | N/A | $8.65 |
| Revenue Next Year | $14.19 | $5.59 |
| P/E Ratio | $24.23 | ★ N/A |
| Revenue Growth | 3.62 | ★ 6.47 |
| 52 Week Low | $47.27 | $10.45 |
| 52 Week High | $108.86 | $18.92 |
| Indicator | LNTH | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 59.50 | 40.00 |
| Support Level | $72.35 | $14.39 |
| Resistance Level | $84.77 | $17.66 |
| Average True Range (ATR) | 2.11 | 0.41 |
| MACD | 0.10 | -0.03 |
| Stochastic Oscillator | 76.01 | 7.00 |
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.